Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular events in patients with psoriasis and psoriatic arthritis treated with JAK/TYK inhibitors: A systematic review and meta-analysis.
Mordehachvili Burlá M, Pera Calvi I, Chahine Chater R, de Moraes-Souza R, Rafalskiy VV, Herranz-Pinto P, Doumat G, Tsoukas M, Haber R. Mordehachvili Burlá M, et al. Among authors: rafalskiy vv. J Eur Acad Dermatol Venereol. 2024 Nov 7. doi: 10.1111/jdv.20418. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39508451 No abstract available.
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV Jr; INSPIRE and COMMAND Study Group. Louis E, et al. JAMA. 2024 Sep 17;332(11):881-897. doi: 10.1001/jama.2024.12414. JAMA. 2024. PMID: 39037800 Free PMC article. Clinical Trial.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
de Mesquita YLL, Pera Calvi I, Reis Marques I, Almeida Cruz S, Padrao EMH, Carvalho PEP, da Silva CHA, Cardoso R, Moura FA, Rafalskiy VV. de Mesquita YLL, et al. Among authors: rafalskiy vv. Int J Obes (Lond). 2023 Oct;47(10):883-892. doi: 10.1038/s41366-023-01337-x. Epub 2023 Jul 17. Int J Obes (Lond). 2023. PMID: 37460681 Review.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III).
Ryzhikov AB, Ryzhikov EA, Bogryantseva MP, Usova SV, Nechaeva EA, Danilenko ED, Pyankov SA, Gudymo AS, Moiseeva AA, Onkhonova GS, Pyankov OV, Sleptsova ES, Lomakin NV, Vasilyeva VS, Tulikov MV, Gusarov VG, Pulin AA, Balalaeva MA, Erofeeva SB, Terpigorev SA, Rychkova OA, Petrov IM, Delian VY, Rafalskiy VV, Tyranovets SV, Gavrilova EV, Maksyutov RA. Ryzhikov AB, et al. Among authors: rafalskiy vv. Vaccines (Basel). 2023 May 18;11(5):998. doi: 10.3390/vaccines11050998. Vaccines (Basel). 2023. PMID: 37243102 Free PMC article.
[The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases].
Stel'makh VV, Kovalenko AL, Popova VB, Uspenskiy YP, Morozov VG, Belikova TN, Rafalskiy VV, Antonova EA. Stel'makh VV, et al. Among authors: rafalskiy vv. Ter Arkh. 2021 Dec 15;93(12):1470-1476. doi: 10.26442/00403660.2021.12.201266. Ter Arkh. 2021. PMID: 36286675 Clinical Trial. Russian.
31 results